Pharmaceutical manufacturing workers form the backbone of resilient domestic and global drug supply chains. They operate in highly regulated, sterile environments to produce, package, and ensure the quality of essential medicines, from everyda...

The India pharma startups ecosystem is stepping into a defining decade. For years, it powered global healthcare as the “Pharmacy of the World,” supplying cost-effective generics at unmatched scale. But in 2026, that identity is no longer enough.

For years, global healthcare has been trying to catch up with one simple reality—patients need better, faster, and more affordable treatment. But the system hasn’t always kept pace. High-cost biologics made life-saving therapies out of reach for...

Explore the evolution of Pharma CDMOs in India and the rise of the CDMO 2.0 model in 2026. Discover key trends, market growth, biologics, digital transformation, and why India is emerging as a global hub for contract development and manufacturing.

Year-end is where most pharma companies slip. Not because of big mistakes—but small misses in tax, filings, and documentation. In 2026, with the industry growing at 9-11%, tighter compliance matters more than ever.

Walk into any urban clinic in India today and you will hear one name migrating from endocrinology journals to dinner-table conversation: semaglutide. Since the drug's Indian patent expired on March 20, 2026, generics from Dr. Reddy's, Sun Pharma...